MedLumics raises €18 million for atrial fibrillation deviceMedLumics has raised another €18 million (around $22 million) to fund clinical trials of its optically-guided imaging system Share XMedLumics raises €18 million for atrial fibrillation devicehttps://pharmaphorum.com/news/medlumics-raises-e18-million-for-atrial-fibrillation-device/
Cash round sets up trial of InteRNA’s microRNA for cancerDutch biotech InteRNA Technologies has raised €18.5 million ($22 million) in second-round financing as it prepares to start Share XCash round sets up trial of InteRNA’s microRNA for cancerhttps://pharmaphorum.com/news/cash-round-sets-up-trial-of-internas-microrna-for-cancer/
UK biotech investment at record levels amid COVID-19New figures have confirmed that the UK’s biotech sector received a massive boost from the COVID-19 pandemic last Share XUK biotech investment at record levels amid COVID-19https://pharmaphorum.com/news/uk-biotech-investment-at-record-levels-amid-covid-19/
VC fund dedicated to psychedelic meds launches in UKIn the last few years, biopharma companies focusing on psychedelic medicines have been springing up like mushrooms – Share XVC fund dedicated to psychedelic meds launches in UKhttps://pharmaphorum.com/news/vc-fund-dedicated-to-psychedelic-meds-launches-in-uk/
Sensyne launches fundraising, agrees patient data deal with PhesiUK digital health firm Sensyne has secured access to millions more anonymised patent records via an alliance with Share XSensyne launches fundraising, agrees patient data deal with Phesihttps://pharmaphorum.com/news/sensyne-launches-fundraising-agrees-patient-data-deal-with-phesi/
German biotech CatalYm raises €50 million for GDF-15 inhibitor immunotherapyCatalYm has closed a €50 million ($59m) series B financing round to fund clinical studies of its immunotherapy Share XGerman biotech CatalYm raises €50 million for GDF-15 inhibitor immunotherapyhttps://pharmaphorum.com/news/german-biotech-catalym-raises-e50-million-for-gdf-15-inhibitor-immunotherapy/
Kyowa Kirin backs €125m life science fund closed by Fountain HealthcareIreland-based Fountain Healthcare Partners has raised another €125 million ($131 million) for its third life sciences fund – Share XKyowa Kirin backs €125m life science fund closed by Fountain Healthcarehttps://pharmaphorum.com/news/kyowa-kirin-backs-e125m-life-science-fund-closed-by-fountain-healthcare/
Sarepta helps bankroll new gene therapy startup AavantiBioSarepta chief commercial officer Bo Cumbo has left to head up gene therapy venture – AavantiBio – with Share XSarepta helps bankroll new gene therapy startup AavantiBiohttps://pharmaphorum.com/news/sarepta-helps-bankroll-new-gene-therapy-startup-aavantibio/
Chord gets $16m to challenge Alexion with oral NMOSD drugSwiss biotech Chord Therapeutics has come out of stealth mode with a $16 million first-round financing that will Share XChord gets $16m to challenge Alexion with oral NMOSD drughttps://pharmaphorum.com/news/chord-gets-16m-to-challenge-alexion-with-oral-nmosd-drug/
